By 2020, the global biosimilars market is expected to top $390 billion and account for up to 28 percent of the global market for pharmaceuticals, due in large part to the loss of patent protection for commercially successful drugs. Read more.
In an analysis of step therapy regulations, GHLF looked at every state bill currently related to step therapy and scored them on how strongly they protected patients on a scale from one to 10. You can also see whether your state has passed or has pending legislation relating to step therapy protocols. Read more.
Stat News explores how insurance companies are becoming more aggressive in their reliance on step therapy, forcing patients to try cheaper treatments before they graduate to more expensive ones, even when providers say the inexpensive drugs will be ineffective. Read more.
In a Drug Channels guest post, Scott Pribyl, CEO of SamplifyRx discusses a new scoring system called RapidPA Score™ for specialty drug prior authorizations, and examines the potential benefits of a cloud-based tool that allows for near real-time prior authorization approvals. Read more.
According to one analysis, approximately 70 percent of patients encountering a prior authorization do not receive the originally prescribed medication. Frost and Sullivan have produced a white paper that offers solutions for physicians, pharmaceutical companies and pharmacists to minimize delays and inefficiencies associated with the prior authorization process. Read more.